---
document_datetime: 2025-12-10 09:48:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/esbriet-epar-all-authorised-presentations_en.pdf
document_name: esbriet-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.5892965
conversion_datetime: 2025-12-27 09:03:16.676419
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging         | Pack size                                       |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------------|-------------------------------------------------|
| EU/1/11/667/007  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)               | 90 tablets                                      |
| EU/1/11/667/008  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)               | 180 (2 x 90) tablets                            |
| EU/1/11/667/009  | Esbriet           | 534 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)               | 21 tablets                                      |
| EU/1/11/667/010  | Esbriet           | 534 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)               | 90 tablets                                      |
| EU/1/11/667/011  | Esbriet           | 801 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)               | 90 tablets                                      |
| EU/1/11/667/012  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | 21 tablets                                      |
| EU/1/11/667/013  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | 42 tablets                                      |
| EU/1/11/667/014  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | 84 tablets                                      |
| EU/1/11/667/015  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | 168 tablets                                     |
| EU/1/11/667/016  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | Initiation pack: 63 (1 x 21 and 2 x 21) tablets |
| EU/1/11/667/017  | Esbriet           | 267 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | 252 (84 x 3) tablets (multipack)                |
| EU/1/11/667/018  | Esbriet           | 801 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | 84 tablets                                      |
| EU/1/11/667/019  | Esbriet           | 801 mg     | Film-coated tablet    | Oral use                  | blister (PVC/Aclar (PCTFE)) | 252 (84 x 3) tablets (multipack)                |